CBD cream shows promise for eczema itch relief in small study
NCT ID NCT07301658
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This 56-day study tested a cream containing CBD and cherimoya fruit extract on 42 children and adults with mild-to-moderate atopic dermatitis (eczema). Participants applied the cream twice daily. Researchers measured skin redness, dryness, itching, and sleep quality. The goal was to see if the cream could improve skin barrier function and comfort.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cream containing cannabidiol (CBD) and Annona cherimola fruit extract
- What this could lead to
- If it works, this could offer a gentle, non-drug option to ease itching and dryness for people with mild-to-moderate atopic dermatitis.
- What could go wrong
- This was a small, completed study with no control group, so results may not be definitive. The cream is a cosmetic product, not a medicine, so benefits may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
42 people
The number who actually took part.
- Started
-
Feb 2023
- Finished
-
Aug 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Sex: both. * Age: from 0 months onwards (includes children and adults). * Atopic-prone skin. * Mild to moderate flare-up. * Skin dryness. * Signed informed consent (by the volunteer or legal guardian as applicable). * Adequate understanding of the clinical study by the participant or legal guardian. * Good physical and psychological health. * No application of any product on the experimental area on the first day of the trial. * Availability to guarantee visits to the research center. Exclusion Criteria: * History of allergies to cosmetic products. * Recent surgery or treatments in the study area. * Oncology patients. * Use of antihistamines and antibiotics within 15 days prior to the start of the study. * Treatment with antihistamines, antibiotics, corticosteroids, immunosuppressants or completion of such treatment within 15 days prior to the start of the study. * Use of any other product for dermatitis during the study. * Sun exposure or UVA rays during the study. * Participation in another clinical study. * Health problems that may compromise adherence to the study protocol.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atopic dermatitis (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
i+Med S.Coop.
Vitoria-Gasteiz, Álava, 01510, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.